<DOC>
	<DOC>NCT02781311</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo and active comparator, finasteride 1 mg once daily, in 18 to 41 years old males with androgenetic alopecia (AGA).</brief_summary>
	<brief_title>Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Participant has androgenetic alopecia (AGA) Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and nonstudy hair growth products during the study. History of hair loss for reasons other than AGA Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth Hairweaving within 6 months Use of hair colorants or dyes within 6 months.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>